Abstracts tagged "Lupus and interferons"

Abstract Number: 1657 • 2017 ACR/ARHP Annual Meeting
SLE Patients with Active Interferon Pathways Showed More Systemic Disease Involvement Than Patients with Inactive Interferon Pathways
Rufei Lu^1,2, Joel M. Guthridge³, Cristina Arriens⁴, Teresa Aberle¹, Stan Kamp¹, Melissa E. Munroe¹, Tim Gross¹, Wade DeJager¹, Susan Macwana¹, Virginia C. Roberts¹, Stephen Apel⁵, Hua Chen¹, Hem Gurung¹, Eliza Chakravarty⁴, Katherine Thanou¹, Joan T. Merrill⁶ and Judith A. James^7,8, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose : Systemic Lupus Erythematosus (SLE) is a clinically diverse disease with a complicated pathophysiology highlighted in part by interferon (IFN) pathway dysregulation. Recent studies…
Abstract Number: 2977 • 2017 ACR/ARHP Annual Meeting
Molecular Phenotypes Associated with Clinical Disease Activity in Adult Systemic Lupus Erythematosus
Rufei Lu¹, Joel M. Guthridge², Cristina Arriens³, Teresa Aberle⁴, Stan Kamp⁴, Melissa E. Munroe⁴, Tim Gross¹, Wade DeJager⁴, Susan Macwana⁴, Virginia C. Roberts⁴, Stephen Apel⁵, Hua Chen⁴, Eliza Chakravarty^6,7, Katherine Thanou⁴, Joan T. Merrill⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose : Remarkable clinical and pathophysiological diversity complicate diagnosis, treatment and therapeutic development in systemic lupus erythematosus (SLE). This study used molecular phenotyping to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].